Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Erlotinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 20 Nov 2015 New trial record